Norinchukin Bank, The Seagen Inc. Transaction History

Norinchukin Bank, The

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $399,106 - $450,477	2,084 New	2,084 $442,000
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $7,317 - $8,043	-39 Reduced 1.57%	2,444 $470,000
Q1 2023 May 12, 2023	BUY	$127.59 - $203.08 $10,334 - $16,449	81 Added 3.37%	2,483 $502,000
Q4 2022 Feb 13, 2023	SELL	$117.37 - $139.17 $20,305 - $24,076	-173 Reduced 6.72%	2,402 $308,000
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $1,217 - $1,620	-9 Reduced 0.35%	2,575 $352,000
Q2 2022 Aug 10, 2022	BUY	$108.81 - $179.33 $74,208 - $122,303	682 Added 35.86%	2,584 $457,000
Q1 2022 May 12, 2022	BUY	$119.61 - $157.85 $45,930 - $60,614	384 Added 25.3%	1,902 $274,000
Q4 2021 Feb 10, 2022	SELL	$142.57 - $190.86 $133,302 - $178,454	-935 Reduced 38.12%	1,518 $235,000
Q3 2021 Nov 09, 2021	BUY	$142.45 - $169.82 $52,564 - $62,663	369 Added 17.71%	2,453 $417,000
Q2 2021 Aug 11, 2021	BUY	$135.08 - $161.1 $42,415 - $50,585	314 Added 17.74%	2,084 $329,000
Q1 2021 May 12, 2021	BUY	$137.51 - $190.8 $75,492 - $104,749	549 Added 44.96%	1,770 $246,000
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $201,013 - $258,766	1,221 New	1,221 $214,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Norinchukin Bank, The, based on Form 13F filings with the SEC.

Stay updated on Norinchukin Bank, The with notifications on news.